Our Approach

Healing the central nervous system & brain through the regulation of serotonin

Based on a proprietary chemistry platform Bright Minds have developed highly selective 5-HT2A and 5-HT2C agonists without 5-HT2B activity.

Healing the brain through innovation

It is no secret that the brain is the most complex organ in the human body. An intricate collection of billions of neurons connected with electrical circuits. Serotonin plays an important role in maintaining normal brain function. Imbalances often lead to mental health problems and neurological ailments. Our team of neuroscientists are driven to create the next generation of serotonin drugs that will precisely target specific conditions leading to a dramatic reduction in side effects and improved therapeutic action transforming patient lives.

Regulating serotonin

Serotonin (5-HT) receptors play a large role in regulation of cognitive function, emotions, memory, and the sleep-wake cycle. Dysfunction in the serotonin system is associated with a number of disease states including neuropsychiatric, seizure, and pain disorders. Bright Minds’ compounds are designed to bring specific serotonin activity back in line with normal levels.

 

We believe that by doing so we will be able to treat a range of disorders. Helping patients return to healthy lives.

Complex systems

14 distinct Serotonin (5-HT) receptor subtypes are widely distributed in the central nervous system, including spinal cord, and the serotonergic system is associated with the regulation of cognitive function, emotions, memory, and the sleep-wake cycle.

 

Serotonin receptors co-localize with cholinergic, GABAergic and glutamatergic neurons. Serotonin receptor agonists have the potential to influence these major neurotransmitter systems to have a profound influence on disease.

We can do better

Currently approved drugs like selective serotonin reuptake inhibitors act by preventing re-uptake of serotonin or modulating the transport of serotonin in the central nervous system, and are not specific to a particular receptor type to influence a neural circuit. As a result, these drugs have side effects, and patients have a limited response to treatment.

The key is precision

Our novel chemical entities are specific serotonin agonists, improving on first generation psychedelic compounds like psilocybin to provide personalized specific drugs to target the serotonin.  We have engineered superior molecules with improvements to the current state of the art including targeting specific serotonin receptors (5-HT2C,  5-HT2A/C  and 5-HT2A) in the brain improving safety and efficacy.